• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.26% Nasdaq Down0.34%

    iBio, Inc. (IBIO)

    0.95 Up 0.01(1.06%) 4:02PM EDT
    |After Hours : 0.95 0.00 (0.00%) 4:55PM EDT - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    iBio, Inc.
    9 Innovation Way
    Suite 100
    Newark, DE 19711
    United States - Map
    Phone: 302-355-0650
    Website: http://www.ibioinc.com

    Index Membership:N/A
    Full Time Employees:7

    Business Summary 

    iBio, Inc., a biotechnology company, focuses on the commercialization of its proprietary plant-based protein expression technologies in the United States and internationally. Its proprietary technologies include iBioLaunch, a transformative platform technology for the development and production of therapeutic proteins and vaccines; and iBioModulator, a technology platform that enhances the potency and duration of the effect of prophylactic and therapeutic vaccines. The company’s product candidates comprise IBIO-CFB03, a product for treatment of idiopathic pulmonary fibrosis; C1 Esterase Inhibitor, a plasma-derived protein; Alpha-Galactosidase, an enzyme replacement protein; and Palivizumab, a monoclonal antibody for the therapeutic protein market. Its vaccine products include H1N1 Influenza and H5N1 Influenza products that have completed Phase I human clinical trials, as well as yellow fever vaccine; malaria and hookworm parasitic pathogen vaccines; and human papillomavirus therapeutic vaccine. The company’s product candidates also comprise Anthrax/Plague bacterial disease vaccine; and Anthrax, a monoclonal antibody for the biodefense market. It has strategic alliances and collaborations with various companies, such as Fraunhofer Center for Molecular Biology, GE Healthcare, FioCruz, and Caliber Biotherapeutics LLC. The company is headquartered in Newark, Delaware.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on iBio, Inc.

    Key Executives 
    Mr. Robert B. Kay , 75
    Exec. Chairman and Chief Exec. Officer
    Mr. Robert L. Erwin , 62
    Mr. Mark Giannone , 58
    Chief Financial Officer
    Mr. Terence E. Ryan Ph.D., 60
    Chief Scientific Officer
    Mr. Douglas Hicks ,
    VP of Bus. Devel.
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders